Cargando…

Interleukin-17 and type 17 helper T cells in cancer management and research

Since their recent discovery, T helper 17 (Th17) cells have been frequently detected in the tumor microenvironment of many malignancies, but their clinical implications remain largely unknown. Interleukin-17 (IL-17) detection is commonly related with poor outcomes in colorectal cancers, yet its pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Llosa, Nicolas J, Geis, Abby L, Thiele Orberg, Erik, Housseau, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918233/
https://www.ncbi.nlm.nih.gov/pubmed/27471699
http://dx.doi.org/10.2147/ITT.S56529
_version_ 1782439084345524224
author Llosa, Nicolas J
Geis, Abby L
Thiele Orberg, Erik
Housseau, Franck
author_facet Llosa, Nicolas J
Geis, Abby L
Thiele Orberg, Erik
Housseau, Franck
author_sort Llosa, Nicolas J
collection PubMed
description Since their recent discovery, T helper 17 (Th17) cells have been frequently detected in the tumor microenvironment of many malignancies, but their clinical implications remain largely unknown. Interleukin-17 (IL-17) detection is commonly related with poor outcomes in colorectal cancers, yet its presence is associated with antitumor responses in ovarian carcinomas. Numerous experimental models illustrate the divergent roles of Th17 cells in tumor immunity, which appears to be mainly dependent on the tumor context (type, location, and stage of cancer). It is recognized that IL-17 is produced by a variety of cell types and that Th17 cells are endowed with a unique functional plasticity. Therefore, when trying to elucidate potential immune biomarkers and immunotargets, it is extremely important to make a clear dissociation between strategies targeting Th17 versus its hallmark cytokine, IL-17. In this review, we will summarize the data regarding the detection of IL-17 and Th17 in human cancers, consider the experimental evidence on their respective roles in antitumor activity, and discuss the potential of IL-17 as an immune target for therapeutic interventions.
format Online
Article
Text
id pubmed-4918233
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49182332016-07-28 Interleukin-17 and type 17 helper T cells in cancer management and research Llosa, Nicolas J Geis, Abby L Thiele Orberg, Erik Housseau, Franck Immunotargets Ther Review Since their recent discovery, T helper 17 (Th17) cells have been frequently detected in the tumor microenvironment of many malignancies, but their clinical implications remain largely unknown. Interleukin-17 (IL-17) detection is commonly related with poor outcomes in colorectal cancers, yet its presence is associated with antitumor responses in ovarian carcinomas. Numerous experimental models illustrate the divergent roles of Th17 cells in tumor immunity, which appears to be mainly dependent on the tumor context (type, location, and stage of cancer). It is recognized that IL-17 is produced by a variety of cell types and that Th17 cells are endowed with a unique functional plasticity. Therefore, when trying to elucidate potential immune biomarkers and immunotargets, it is extremely important to make a clear dissociation between strategies targeting Th17 versus its hallmark cytokine, IL-17. In this review, we will summarize the data regarding the detection of IL-17 and Th17 in human cancers, consider the experimental evidence on their respective roles in antitumor activity, and discuss the potential of IL-17 as an immune target for therapeutic interventions. Dove Medical Press 2014-03-10 /pmc/articles/PMC4918233/ /pubmed/27471699 http://dx.doi.org/10.2147/ITT.S56529 Text en © 2014 Llosa et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Llosa, Nicolas J
Geis, Abby L
Thiele Orberg, Erik
Housseau, Franck
Interleukin-17 and type 17 helper T cells in cancer management and research
title Interleukin-17 and type 17 helper T cells in cancer management and research
title_full Interleukin-17 and type 17 helper T cells in cancer management and research
title_fullStr Interleukin-17 and type 17 helper T cells in cancer management and research
title_full_unstemmed Interleukin-17 and type 17 helper T cells in cancer management and research
title_short Interleukin-17 and type 17 helper T cells in cancer management and research
title_sort interleukin-17 and type 17 helper t cells in cancer management and research
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918233/
https://www.ncbi.nlm.nih.gov/pubmed/27471699
http://dx.doi.org/10.2147/ITT.S56529
work_keys_str_mv AT llosanicolasj interleukin17andtype17helpertcellsincancermanagementandresearch
AT geisabbyl interleukin17andtype17helpertcellsincancermanagementandresearch
AT thieleorbergerik interleukin17andtype17helpertcellsincancermanagementandresearch
AT housseaufranck interleukin17andtype17helpertcellsincancermanagementandresearch